Roisin Worsley

Roisin Worsley

Auto-generated profile, based on publicly available information

Roisin Worsley

Monash Alfred Psychiatry research centre, Monash University and The Alfred Hospital, Central Clinical School, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2014 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
JKJ Kulkarni
J Kulkarni
EGE Gavrilidis
E Gavrilidis
WWW Wang
W Wang
RWR Worsley
R Worsley
PFPaul B Fitzgerald
Paul B Fitzgerald
HBH Burger
H Burger

1 July 2015 in Menopause
Verified
Journal Article
Closed access
PGPragya Msc Gartoulla
Pragya Msc Gartoulla
RWRoisin Mbbs Worsley
Roisin Mbbs Worsley
RBRobin J. Mbbs Bell
Robin J. Mbbs Bell
SDSusan R. Mbbs Davis
Susan R. Mbbs Davis
Objective This study aims to determine the prevalence and severity of menopausal symptoms in older postmenopausal women and, hence, the need for treatment options for women of this age. Methods This is a cross-sectional questionnaire-based study conducted between October 2013 and March 2014 among 2,020 women aged 40 to 65 years and living independently across Australia. The main outcome measures were the prevalence of moderate to severe vasomotor symptoms (VMS), as measured by the Menopause-Specific Quality of Life Questionnaire, and the current use of prescription therapy for menopausal symptoms. Results The prevalence of moderate to severe VMS was as follows: 2.8% in premenopausal women, 17.1% in perimenopausal women, 28.5% in postmenopausal women younger than 55 years, 15.1% in postmenopausal women aged 55 to 59 years, and 6.5% in postmenopausal women aged 60 to 65 years. Prescription therapy for menopausal symptoms was used by 135 women: 120 (5.9%) women using hormone therapy and 15 (0.7%) women using nonhormonal medication. The factors positively associated with moderate to severe VMS were smoking (odds ratio, 1.6; 95% CI, 1.1-2.3; P < 0.05) and a body mass index of 25 to 29.9 kg/m2 (odds ratio, 1.7; 95% CI, 1.1-2.5; P < 0.05); education beyond high school was inversely associated (odds ratio, 0.7; 95% CI, 0.5-0.9; P < 0.05). Conclusions In this large, representative, community-based sample of women, there is a high prevalence of untreated moderate to severe VMS even in women aged 60 to 65 years. The use of vaginal estrogen and nonhormonal prescription therapy with proven efficacy for treatment of menopausal symptoms is strikingly low, suggesting that menopause remains an undertreated condition.

1 August 2014 in Contraception
Verified
Journal Article
Closed access
AWAnnabelle M. Warren
Annabelle M. Warren
Caroline GurvichCaroline Gurvich
Caroline Gurvich
RWRoisin Worsley
Roisin Worsley
JKJayashri Kulkarni
Jayashri Kulkarni

1 February 2016 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
SDSusan R. Davis
Susan R. Davis
RWRoisin Worsley
Roisin Worsley
KMKaren K. Miller
Karen K. Miller
SPSharon J. Parish
Sharon J. Parish
NSNanette Santoro
Nanette Santoro
Introduction: Androgens have been implicated as important for female sexual function and dysfunction. Aim: To review the role of androgens in the physiology and pathophysiology of female sexual functioning and the evidence for efficacy of androgen therapy for female sexual dysfunction (FSD). Methods: We searched the literature using online databases for studies pertaining to androgens and female sexual function. Major reviews were included and their findings were summarized to avoid replicating their content. Main Outcome Measures: Quality of data published in the literature and recommendations were based on the GRADES system. Results: The literature supports an important role for androgens in female sexual function. There is no blood androgen level below which women can be classified as having androgen deficiency. Clinical trials have consistently demonstrated that transdermal testosterone (T) therapy improves sexual function and sexual satisfaction in women who have been assessed as having hypoactive sexual desire disorder. The use of T therapy is limited by the lack of approved formulations for women and long-term safety data. Most studies do not support the use of systemic dehydroepiandrosterone therapy for the treatment of FSD in women with normally functioning adrenals or adrenal insufficiency. Studies evaluating the efficacy and safety of vaginal testosterone and dehydroepiandrosterone for the treatment of vulvovaginal atrophy are ongoing. Conclusion: Available data support an important role of androgens in female sexual function and dysfunction and efficacy of transdermal T therapy for the treatment of some women with FSD. Approved T formulations for women are generally unavailable. In consequence, the prescribing of T mostly involves off-label use of T products formulated for men and individually compounded T formulations. Long-term studies to determine the safety of T therapy for women and possible benefits beyond that of sexual function are greatly needed.

1 March 2016 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
NSNanette Santoro
Nanette Santoro
RWRoisin Worsley
Roisin Worsley
KMKaren K. Miller
Karen K. Miller
SPSharon J. Parish
Sharon J. Parish
SDSusan R. Davis
Susan R. Davis
Introduction: Sex steroids are important in female sexual function and dysfunction.Aim: To review the role of estrogens in the physiology and pathophysiology of female sexual functioning and the evidence for efficacy of estrogen therapy for female sexual dysfunction to update the previously published International Society of Sexual Medicine Consensus on this topic.Methods: Panel members reviewed the published literature using online databases for studies pertaining to estrogen in female sexual function and dysfunction. Attention was specifically given to clinical trials that had reported on sexual function outcomes in women treated with estrogen.Main Outcome Measures: Quality of data published in the literature and recommendations were based on the GRADES system.Results: Observational studies that have considered relationship factors and physical or mental health have reported that these factors contribute more to sexual functioning than menopausal status or estrogen levels. Few clinical trials have investigated estrogen therapy with sexual function as a primary outcome. The available data do not support systemic estrogen therapy for the treatment of female sexual dysfunction. Topical vaginal estrogen therapy improves sexual function in postmenopausal women with vulvovaginal atrophy (VVA) and is considered first-line treatment of VVA. Oral ospemifene, a selective estrogen receptor modulator, is effective for the treatment of VVA and might have independent systemic effects on female sexual function.Conclusion: For sexual problems, the treatment of VVA remains the most pertinent indication for estrogen therapy. When systemic symptoms are absent, estrogen therapy ideally can be administered by a vaginal preparation alone. Systemic estrogen therapy with combined estrogen and progestin in non-hysterectomized women is indicated for women who require treatment for vasomotor and/or other systemic estrogen deficiency symptoms. The improvement in well-being achieved by relief of vasomotor and other symptoms might improve libido in some women and abrogate further intervention.

1 February 2014 in Maturitas
Verified
Journal Article
Closed access
RWRoisin Worsley
Roisin Worsley
RBRobin Bell
Robin Bell
JKJayashri Kulkarni
Jayashri Kulkarni
SDSusan R. Davis
Susan R. Davis